

BSCC Abstract Template

Lecture Title:	Automated solutions for diagnostic HPV testing to address changing volumes of testing
Lecturer Name:	Dr Geraldine Roeder
Lecturer Biography:	Dr Geraldine Roeder is Market Development Manager, Northern Europe for Women's Health products at QIAGEN. Prior to joining QIAGEN she held sales and marketing positions at 3M Health care and Gambro Renal Products. Her PhD thesis was titled "Gene Therapy for Cervical Cancer" and she has maintained an interest in the link between HPV and Cervical Cancer since that time.
Abstract	<p>As the Sentinel Sites project continues and the data supporting the use of Human Papillomavirus testing grows¹⁻³, it seems likely that HPV triage testing may be adopted in England in the near future.</p> <p>The <i>digene</i> HPV test from QIAGEN (Hybrid Capture 2) has been shown to have exquisite clinical sensitivity for high grade cervical disease in numerous large scale clinical studies and to reduce incidence and mortality from cervical cancer. Hybrid Capture 2 can be automated on the Rapid Capture System, and QIAGEN have recently developed the QIAensemble series of instruments, a cutting-edge next-generation diagnostic system for HPV. QIAensemble automates all steps including sample loading, target denature, probe hybridization, target capture, signal production, signal detection and assay result reporting. This automated system has been designed to generate up to 400 clinical results per 8 hr shift.</p> <p>The QIAensemble system runs the enhanced Hybrid Capture assay (eHC) which is designed to capitalise on the clinical sensitivity of Hybrid Capture 2 for high grade cervical disease, whilst creating a highly specific result . Here we present preliminary data on the eHC assay and the QIAensemble series of instruments.</p>
Take home message(s)	<ul style="list-style-type: none"> - HPV testing using HC2 can reduce the incidence and mortality from cervical cancer⁴. - HC2 is the gold standard HPV test and has been clinically validated in numerous randomized controlled trials¹⁻⁵. - The QIAensemble system is a fully automated, true walk-away system for HPV testing based on proven hybrid capture technology. - The throughput of the QIAensemble system is flexible, is cost effective from an average of 10+ samples per day and allows testing of up to 400 clinical specimens in an 8 hour shift. - Preliminary data shows that the eHC assay maintains the clinical sensitivity of Hybrid Capture 2 but shows enhanced specificity

<p style="text-align: center;">References</p>	<p>1. Moss, K., et al. (2006) Effect of testing for human papillomavirus as a triage during screening for cervical observational before and after study BMJ. 332, 83.</p> <p>2. Legood, R., et al. (2006) Lifetime effects, costs and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ. 332, 790.</p> <p>3. Cuzick, J., et al. (2008) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - results from the Hammersmith study. Int. J. Cancer 122, 2294.</p> <p>4. Sankaranarayanan R et al. (2009) HPV Screening for Cervical Cancer in India. NEJM 360,1385-1394</p> <p>5. Meijer et al (2009) Guidelines for Human Papillomavirus DNA tes requirements for primary cervical screening in women 30 years and older. Int. J. Cancer 124, 516-520</p>
<p style="text-align: center;">Declaration of interest</p>	<p>Dr Geraldine Roeder is employed by QIAGEN UK Ltd.</p>